References
- Starc TJ. Erythrocyte macrocytosis in infants and children with Down syndrome. J Pediatr. 1992;121(4):578–581.
- Roizen NJ, Amarose AP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet. 1993;46(5):510–512. doi:10.1002/ajmg.1320460509.
- David O, Fiorucci GC, Tosi MT, et al. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol. 1996;13(3):271–275.
- Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44(1):29–32. doi:10.1002/pbc.20141.
- Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110(3):512–524.
- Choi JK. Hematopoietic disorders in Down syndrome. Int J Clin Exp Pathol. 2008;1(5):387–395.
- Stary J, Baumann I, Creutzig U, Harbott J, Michalova K, Niemeyer C. Getting the numbers straight in pediatric MDS: Distribution of subtypes after exclusion of down syndrome. Pediatr Blood Cancer. 2008;50(2):435–436. doi:10.1002/pbc.21235.
- Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277–282. doi:10.1038/sj.leu.2402765.
- Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: A report from the Children's Oncology Group AAML0431 trial. Blood. 2017;129(25):3304–3313.
- Fleischman RA, Stockton SS, Cogle CR. Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2. Leuk Res. 2017;61:104–107. doi:10.1016/j.leukres.2017.09.002.
- Inoue D, Bradley RK, Abdel-Wahab O. Spliceosomal gene mutations in myelodysplasia: Molecular links to clonal abnormalities of hematopoiesis. Genes Dev. 2016;30(9):989–1001. doi:10.1101/gad.278424.116.
- Madan V, Kanojia D, Li J, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.
- Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012;119(14):3211–3218. doi:10.1182/blood-2011-12-400994.
- Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617–630. doi:10.1016/j.ccell.2015.04.006.
- Maloney KW, Taub JW, Ravindranath Y, Roberts I, Vyas P. Down syndrome preleukemia and leukemia. Pediatr Clin North Am. 2015;62(1):121–137. doi:10.1016/j.pcl.2014.09.009.
- Wachtel TJ, Pueschel SM. Macrocytosis in Down syndrome. Am J Ment Retard. 1991;95(4):417–420.
- Langebrake C, Klusmann JH, Wortmann K, Kolar M, Puhlmann U, Reinhardt D. Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down’s syndrome. Haematologica. 2006;91(11):1473–1480.
- Turunen JJ, Niemelä EH, Verma B, Frilander MJ. The significant other: Splicing by the minor spliceosome. Wires RNA. 2013;4(1):61–76. doi:10.1002/wrna.1141.
- Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated genes/pathways and clinical associations. Blood. 2018;132(12):1225–1240. doi:10.1182/blood-2018-04-843771.
- Pimentel H, Parra M, Gee S, et al. A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis. Nucleic Acids Res. 2014;42(6):4031–4042. doi:10.1093/nar/gkt1388.
- Pimentel H, Parra M, Gee SL, Mohandas N, Pachter L, Conboy JG. A dynamic intron retention program enriched in RNA processing genes regulates gene expression during terminal erythropoiesis. Nucleic Acids Res. 2016;44(2):838–851. doi:10.1093/nar/gkv1168.